Hormonal
Simultaneous administration of Growth Hormone (GH) and Insulin-like Growth Factor I (IGF-I) produces significantly greater nitrogen retention (anabolism) than either agent administered alone.
For individuals in a catabolic state (e.g., severe caloric restriction), using Growth Hormone and IGF-I together yields significantly better muscle preservation than using either hormone alone. The combination not only maximizes nitrogen retention but also stabilizes blood glucose levels, mitigating the hypoglycemic risk of IGF-I and the hyperglycemic risk of GH. This suggests that combination therapy is superior for treating severe catabolism, though it requires careful medical supervision due to the potency of both agents.
These results suggest that the combination of GH and IGF-I treatment is substantially more anabolic than either IGF-I or GH alone.
Why this rating
Randomized, controlled, crossover trial in healthy humans, though with a small sample size (n=7).
Source
Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.
Stuart Kupfer et al. · Journal of Clinical Investigation · 1993
DOI 10.1172/jci116212
More from this paper
- The combination of GH and IGF-I attenuates the hypoglycemia caused by IGF-I alone while maintaining better glucose tolerance than GH alone.Good
- The combination of GH and IGF-I increases serum IGF-I concentrations and stabilizes the IGF-I pool by inducing IGFBP-3 and Acid-Labile Subunit (ALS), leading to greater anabolic efficacy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →